Skip to content

Clinical trials

Observational Atherosclerosis trials in the Netherlands

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Atherosclerosis Phase: Observational Country / region: Netherlands Clear all

29 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20071
20094
20101
20122
20144
20153
20172
20181
20191
20201
20211
20221
20231
20241
20252
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Recruiting7
Unknown status4
Active, not recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Radboud University Medical Center5
Maastricht University Medical Center4
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)3
Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)2
Infraredx2
AstraZeneca1
Biotronik AG1
Cambridge University Hospitals NHS Foundation Trust1
Clinical Operations WCN B.V.1
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Atherosclerosis29
Coronary Artery Disease11
Cardiovascular Diseases9
Dyslipidemias3
Homozygous Familial Hypercholesterolemia3
Hypertension3
Lipid Metabolism Disorders3
Myocardial Infarction3
Myocardial Ischemia3
Peripheral Arterial Disease3

Trials

Showing 1 to 25 of 29. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.